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Abstract
Quinine remains an important anti-malarial drug almost 400 years after its effectiveness was first documented.
However, its continued use is challenged by its poor tolerability, poor compliance with complex dosing regimens,
and the availability of more efficacious anti-malarial drugs. This article reviews the historical role of quinine,
considers its current usage and provides insight into its appropriate future use in the treatment of malaria. In light
of recent research findings intravenous artesunate should be the first-line drug for severe malaria, with quinine as
an alternative. The role of rectal quinine as pre-referral treatment for severe malaria has not been fully explored,
but it remains a promising intervention. In pregnancy, quinine continues to play a critical role in the management
of malaria, especially in the first trimester, and it will remain a mainstay of treatment until safer alternatives become
available. For uncomplicated malaria, artemisinin-based combination therapy (ACT) offers a better option than
quinine though the difficulty of maintaining a steady supply of ACT in resource-limited settings renders the rapid
withdrawal of quinine for uncomplicated malaria cases risky. The best approach would be to identify solutions to
ACT stock-outs, maintain quinine in case of ACT stock-outs, and evaluate strategies for improving quinine
treatment outcomes by combining it with antibiotics. In HIV and TB infected populations, concerns about potential
interactions between quinine and antiretroviral and anti-tuberculosis drugs exist, and these will need further
research and pharmacovigilance.
Background and historical perspective
The discovery of quinine is considered the most seren-
dipitous medical discovery of the 17th century [1] and
malaria treatment with quinine marked the first success-
ful use of a chemical compound to treat an infectious
disease[2]. Quinine, as a component of the bark of the
cinchona (quina-quina) tree, was used to treat malaria
from as early as the 1600s, when it was referred to as
the “Jesuits’ bark,” “cardinal’s bark,” or “sacred bark.”
These names stem from its use in 1630 by Jesuit mis-
sionaries in South America, though a legend suggests
earlier use by the native population[2]. According to
this legend, an Indian with a high fever was lost in an
Andean jungle. Thirsty, he drank from a pool of stag-
nant water and found that it tasted bitter. Realizing that
the water had been contaminated by the surrounding
quina-quina trees he thought he was poisoned.
Surprisingly, his fever soon abated, and he shared this
accidental discovery with fellow villagers, who thereafter
used extracts from the quina-quina bark to treat fever
[3]. The legend of quinine’s discovery accepted in Eur-
ope differs though, and involves the Spanish Countess
of Chinchon who, while in Peru, contracted a fever that
was cured by the bark of a tree. Returning to Spain with
the bark, she introduced quinine to Europe in 1638 and,
in 1742, botanist Carl Linnaeus called the tree “Cinch-
ona” in her honour [4].
Before 1820, the bark of the cinchona tree was first
dried, ground to a fine powder, and then mixed into a
liquid (commonly wine) before being drunk. In 1820,
quinine was extracted from the bark, isolated and
named by Pierre Joseph Pelletier and Joseph Caventou.
Purified quinine then replaced the bark as the standard
treatment for malaria [5]. Quinine and other cinchona
alkaloids including quinidine, cinchonine and cinchoni-
dine are all effective against malaria. The efficacies of
these four alkaloids were evaluated in one of the earliest
clinical trials, conducted from 1866 to 1868 in 3600
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patients using prepared sulfates of the alkaloids. With
the main outcome measure of “cessation of febrile par-
oxysms”, all four alkaloids were found to be comparable,
with cure rates of >98%[6]. However, after 1890 quinine
became the predominantly used alkaloid, mainly due to
a change in supply from South American to Javan
cinchona bark, which contained a higher proportion of
quinine [7]. Quinine remained the mainstay of malaria
treatment until the 1920s, when more effective synthetic
anti-malarials became available. The most important of
these drugs was chloroquine, which was extensively
used, especially beginning in the 1940s [6]. With heavy
use, chloroquine resistance developed slowly. Resistance
of Plasmodium falciparum to chloroquine was seen in
parts of Southeast Asia and South America by the late
1950s, and was widespread in almost all areas with falci-
parum malaria by the 1980s. With increasing resistance
to chloroquine, quinine again played a key role, particu-
larly in the treatment of severe malaria [6]. To-date qui-
nine continues to play a significant role in the
management of malaria. This review, discusses the his-
torical role of quinine, considers its current usage, and
provides insight into the appropriate future use of qui-
nine for the treatment of malaria. Information was
obtained by searching published literature in the
National Library of Medicine via Pub Med and MED-
LINE search engines for research articles, reviews,
books, and other reports. Identification of published
reports was done using key word searches such as qui-
nine and malaria treatment, quinine and drug resistance,
quinine in pregnancy, quinine and antibiotic combina-
tions, and quinine and HIV/TB infected populations.
Quinine properties
Quinine is a cinchona alkaloid that belongs to the aryl
amino alcohol group of drugs. It is an extremely basic
compound and is, therefore, always presented as a salt
[6]. Various preparations exist, including the hydro-
chloride, dihydrochloride, sulphate, bisulphate, and glu-
conate salts; of these the dihydrochloride is the most
widely used. Quinine has rapid schizonticidal action
against intra-erythrocytic malaria parasites. It is also
gametocytocidal for Plasmodium vivax and Plasmodium
malariae, but not for Plasmodium falciparum. Quinine
also has analgesic, but not antipyretic properties. The
anti-malarial mechanism of action of quinine is
unknown.
Quinine is rapidly absorbed both orally and parenter-
ally, reaching peak concentrations within 1-3 hours[8].
It is distributed throughout the body fluids and is highly
protein bound, mainly to alpha-1 acid glycoprotein. The
binding capacity in plasma is concentration dependent,
but also depends on the levels of alpha-1 acid glycopro-
tein, which therefore makes comparisons between
different studies difficult[9]. Quinine readily crosses the
placental barrier and is also found in cerebral spinal
fluid. Excretion is rapid - 80% of the administered drug
is eliminated by hepatic biotransformation and the
remaining 20% is excreted unchanged by the kidney
[10-12]. The half-life of quinine ranges between 11-18
hours [13,14]. Several pharmacokinetic characteristics of
quinine differ according to the age of the subject and
are also affected by malaria. The volume of distribution
is less in young children than in adults, and the rate of
elimination is slower in the elderly than in young adults.
In patients with acute malaria the volume of distribution
is reduced and systemic clearance is slower than in
healthy subjects; these changes are proportional to the
severity of the disease. As a result, plasma quinine levels
are higher in patients with malaria. Protein binding of
quinine is increased in patients with malaria as a result
of an increased circulating concentration of alpha-1 acid
glycoprotein [15].
Quinine has a low therapeutic index, and adverse
effects with its use are substantial [16]. The side effects
commonly seen at therapeutic concentrations are
referred to as cinchonism, with mild forms including
tinnitus, slight impairment of hearing, headache and
nausea. Impairment of hearing is usually concentration
dependent and reversible [17]. More severe manifesta-
tions include vertigo, vomiting, abdominal pain, diar-
rhea, marked auditory loss, and visual symptoms,
including loss of vision. Hypotension may occur if the
drug is given too rapidly, and venous thrombosis may
occur following intravenous injections [10]. Intramuscu-
lar administration is painful and may cause sterile
abscesses. Hypoglycaemia is yet another common side
effect of quinine therapy [15,18] and is a particular pro-
blem in pregnant women[19]. Hypoglycaemia has been
reported to occur in up to 32% of patients receiving qui-
nine therapy[18]. However in more recent studies, hypo-
glycaemia occurred in only 3% of adults and 2.8% of
African children receiving quinine [20,21]. Less frequent
but more serious side effects of quinine therapy include
skin eruptions, asthma, thrombocytopaenia, hepatic
injury and psychosis [22].
Overview of quinine use in the management of
malaria
Quinine remains an important anti-malarial drug,
almost 400 years after Jesuit priests first documented its
effectiveness. The 2010 World Health Organisation
(WHO) guidelines recommend a combination of quinine
plus doxycycline, tetracycline or clindamycin as second-
line treatment for uncomplicated malaria (to be used
when the first-line drug fails or is not available) and qui-
nine plus clindamycin for treatment of malaria in the
first trimester of pregnancy [23]. Based on recent trials,
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intravenous artesunate should be used for the treatment
of severe falciparum malaria in adults [20] and children
[21], in preference to quinine.
By 2009, 31 African countries recommended quinine
as second-line treatment for uncomplicated malaria, 38
as first-line treatment of severe malaria and 32 for treat-
ment of malaria in the first trimester of pregnancy [24].
In most of Africa, quinine is still used as monotherapy,
contrary to the WHO recommendations[23,24]; the rea-
son for this practice may be the higher costs of quinine-
antibiotic combinations. Quinine continues to play a sig-
nificant role in the management of malaria in sub-
Saharan Africa and other malaria endemic areas, and its
use in routine practice may not be restricted to the sta-
ted WHO recommendations. In Cameroon, even one
year after the introduction of ACT, quinine continued
to be used as first-line therapy, with 45% of adults
receiving oral quinine for uncomplicated malaria [25].
Recent surveillance data from sentinel sites in Uganda
showed that quinine was prescribed for up to 90% of
children < 5 years with uncomplicated malaria [26].
The use of quinine for uncomplicated malaria cases
should have decreased due to toxicities, poor compli-
ance and the implementation of newer and better toler-
ated therapies such as ACT. However, the limited
availability of ACT and the increasing resistance to
chloroquine and antifolates have actually increased its
use in recent times [27]. Therefore, studies evaluating
the role of quinine in the management of malaria have
been reviewed.
Quinine for uncomplicated malaria
In several settings, oral quinine continues to be used as
treatment for uncomplicated malaria, a practice mainly
resulting from frequent stock-outs of the recommended
ACT [26,28]. Previous studies of the effectiveness and
efficacy of quinine for uncomplicated malaria showed
mixed results (Table 1). The majority of these studies
were conducted in settings with reported declining effi-
cacy of quinine in Southeast Asia and South America.
Earlier studies in these regions, using varying dosing regi-
mens, showed cure rates ranging from 76% to 98%. The
lower cure rates were mainly observed with shorter regi-
mens (3 days) and higher cure rates when the drug was
combined with sulphadoxine-pyrimethamine, tetracycline
or clindamycin [29-34]. Similar findings were reported in
Vietnam, where a three-day course of quinine plus arte-
sunate had a cure rate of only 50%, compared to a five-
day course, which had a cure rate of 76%[35]. Studies in
Southeast Asia using quinine monotherapy for 7 days
showed cure rates of 85-87% [29,33], which is similar to
what was observed over 15 years earlier [36], (Table 1).
Moreover, the addition of either tetracycline or clinda-
mycin to quinine in the Thai study improved cure rates
to 98% and 100% respectively and also delayed the
appearance of Plasmodium vivax infection, suggesting
additional activity against this species [33].
In Africa, studies evaluating three-day quinine treat-
ment regimens have usually found unacceptably high
failure rates [37], with recurrent infections at day 28
post-treatment experienced in 30% - 50% of patients
[37-39]. However most of these studies did not perform
PCR analyses to distinguish between recrudescence and
re-infection, leading to possible underestimation of effi-
cacy. In interpreting these results, the malaria transmis-
sion intensity at the study sites needs to be taken into
consideration, as high treatment failure rates in high
transmission settings may be due to a high risk of new
infections. Additional PCR unadjusted studies that have
evaluated five-day regimens of quinine have found
recurrent infection rates on day 7 between 4% and 7%
[40] and day 14 treatment failure rates of 0 to 5%
(Table 1) [41,42]. In Equatorial Guinea, five-day courses
of quinine were associated with day 14 PCR unadjusted
failure rates as high as 22%. These latter results
prompted a change in the quinine treatment regimen
for this region to a 7 day course, with subsequent signif-
icant decrease in treatment failure rates to 3%-5.5% [43].
This study also reported that treatment failure rates
with quinine remained stable over the five-year period
of surveillance.
Even with seven-day treatment durations, evaluations
of different quinine dosage regimens have revealed
interesting trends. Doses of 10 mg/kg/day given twice
daily for 7 days were associated with day 28 treatment
failure rates as high as 30%[37]. Increasing the quinine
dosage to 15 mg/kg/day or 20 mg/kg/day improved
treatment outcomes, with failure rates ranging from 8%
to 14%[37], although potential increases in toxicity with
higher dosages are a concern. The treatment regimen
currently recommended in sub-Saharan Africa is 10 mg/
kg of the base given 8 hourly for 7 days. This regimen
was associated with a lower rate of recurrent infections
on day 28 (6.3%) compared to the 10 mg/kg twice daily
regimen (16.1%)[44].
The advent of ACT has provided important new ther-
apeutic options for the management of uncomplicated
malaria in regions with high prevalence of multi-drug
resistant malaria. A few available trials have shown
superiority of ACT over quinine in the management of
uncomplicated malaria [32,45,46]. In Brazil, patients
treated with artemether-lumefantrine (AL) had signifi-
cantly faster parasite clearance times when compared to
those treated with quinine+doxycycline [46]. Consider-
ing the extensive available data, quinine should not be
used to treat uncomplicated malaria when ACT is avail-
able [27,45]. ACT has the advantages of simplicity of
dosing, which promotes adherence to therapy when
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Table 1 Summary of studies of quinine for the treatment of uncomplicated malaria
Study site Year Sample size
and study
population
Drug Regimens Duration
of follow-
up
Treatment
outcome
Comment Reference
Thailand, region with
multidrug resistant
malaria
1984-
1985
66 children
2-12 years
Quinine
Quinidine
28 days
DOT
Cure rates:
Quinine -
85%
Quinidine -
88%
Treatment failures only RI
responses
[29]
Cambodia, region with
multidrug resistant
malaria
1983 119 adults,
>15 years
Mefloquine +SP
(MSP)
3 days quinine
+tetracycline
(Q3T7)
7 days of quinine
+ tetracycline
(Q7T7)
28 days
DOT
Cure rates:
MSP: 98%
Q3T7: 76%
Q7T7: 92%
Q7T7 still gives good cure rate [30]
Brazil, setting with
quinine resistance
1985 100 patients
18-55 years
Mefloquine 1000
mg single dose
(MQ)
3 days quinine
+SP (Q3+SP)
42 days
DOT
Cure rates:
MQ:
96%
Q3 + SP: 98%
Four RI responses in Q3 + SP
group
[31]
Thailand, region with
multidrug resistant
malaria
1994 102 patients
16-60 years
Mefloquine
+tetracycline
(MQT)
7 days of Quinine
+ tetracycline
(Q7T7)
28 days
DOT
Cure rates:
MQT: 94%
Q7T7: 98%
MQ + Tetra as effective as Q7T7 [34]
Thailand, region with
multidrug resistant
malaria
1995-
1997
204 male
patients
15-64 years
7 days quinine
(Q7)
Quinine +
tetracycline
(Q7T7)
Quinine +
clindamycin
(Q7C7)
28 days
Directly
observed
therapy
Cure rates:
Q7: 87%
Q7T7: 98%
Q7C7: 100%
Tetracycline or clindamycin
improves quinine cure rates
[33]
Equatorial Guinea,
setting with no quinine
resistance
1999 114 children
6-59 months
7days quinine
(Q7)
Chloroquine (CQ)
Sulfadoxine/
pyrimethamine
(SP)
114 day
follow-up
Cure rates:
Q7: 94.5%
CQ: 60%
SP: 90%
Quinine is effective against P.
falciparum malaria
[43]
Cameroon, High
transmission setting
2005 30 children
0.5-6 years
5 days quinine
(Q5)
14 day
follow-up
Cure rates:
100%
[41]
Burundi Perennial
transmission setting
1992-
1995
472 children
0-14 years
Chloroquine (CQ)
5 days quinine
(Q5)
7 day
follow-up
Failure rates
Q5:
1992-1993:
4.2%
1994-1995:
7.1%
[40]
Guinea-Bissau Perennial
transmission setting
1994-
1995
203 children
0.7-13 years
3 days quinine
(Q3)
5 days quinine
(Q5)
7 days quinine
(Q7)
28-35 day
follow-up
Day 28
recurrent
parasitemia:
Q3: 79%
Q5: 90%
Q7: 11%
3 day quinine regimens should
not be used.
[37]
Gabon High
transmission setting
1993-
1994
120 adults =
15years
3 days quinine
(Q3)
3 days quinine
+clindamycin
(Q3C3)
3 days quinine
+doxycycline
(Q3D3)
28 day
follow-up
Day 28 cure
rates:
Q3: 38%
Q3C3: 92%
Q3D3: 91%
The two short course
combinations of quinine had
excellent cure rates
[109]
Uganda Meso-endemic
transmission setting
2007-
2008
175 children
6months - 5
years
7 days quinine
(Q7)
3 days
artemether-
lumefantrine (AL)
28 day
follow-up
Cure rates:
Q7: 64%
AL: 97%
Results question the advisability of
quinine use for uncomplicated
malaria
[45]
Achan et al. Malaria Journal 2011, 10:144
http://www.malariajournal.com/content/10/1/144
Page 4 of 12
compared with the seven-day treatment courses of qui-
nine [32,45], better tolerance and decreased risks of ser-
ious toxicity.
Nevertheless, despite their scale up in Africa, the cost
and availability of ACT in the public sector remains a
major challenge. In 2008, ACT coverage in the public
sector in high-burden African countries was only 42%
[47]. Similarly, a survey carried out during the same
year in seven African countries showed that the percen-
tage of fever cases in children < 5 years treated with
ACT was only 16% [47]. The sustainability of ACT sup-
plies in resource limited settings therefore presents a
huge problem, with stock-outs consistently occurring in
health facilities [48]. Quinine, on the other hand, is a
relatively cheap drug and often the only available option,
rendering its rapid withdrawal for uncomplicated
malaria cases risky. The best approach in these settings
would be to proactively identify solutions to ACT stock-
outs and maintain quinine as a fall-back drug only in
case of ACT stock-outs. Additionally, improving quinine
treatment outcomes by combining it with antibiotics,
such as tetracycline or clindamycin [49-51], could be
investigated and promoted. More recently, combinations
of quinine and newer antibiotics with shorter treatment
regimens that would improve adherence to therapy as
well as minimize related adverse events have been evalu-
ated. One such combination is that with azithromycin
which is of particular interest, as the drugs act synergis-
tically [52]. This combination offers promise for use
especially in pregnant women and children < 8 years,
since, unlike tetracyclines, both drugs are safe in these
groups. A study in Thailand showed comparable efficacy
in the treatment of multidrug resistant malaria, with
cure rates of 100%, for a seven-day course of quinine
+doxycycline and a three-day course of quinine+azithro-
mycin [49]. These drug combinations will need further
evaluation to confirm these findings and may offer a
solution to the compliance problems associated with
seven-day courses of quinine.
Quinine for malaria in pregnancy
Malaria in pregnancy causes several adverse outcomes
that include maternal anaemia, intrauterine growth
retardation, low birth weight, preterm deliveries and
abortion. Prevention and treatment of malaria in preg-
nancy is, therefore, critical to avoid these adverse out-
comes. Currently the WHO recommends the use of
quinine plus clindamycin for treating malaria in the first
trimester of pregnancy, as the safety of artemisinin com-
pounds during this period is not yet established [23]. As
most clinical trials exclude women in their first trime-
ster of pregnancy, information on the efficacy and safety
of anti-malarial drugs during this period is extremely
limited. Evidence for the safety of quinine in pregnancy
is mostly historical and there are few clinical trials pub-
lished [50,53]. Clindamycin on the other hand has a
good safety record in pregnancy [54] and its pharmaco-
kinetic properties are usually unchanged by pregnancy
[55]. The combination of quinine and clindamycin has
proven highly efficacious against multidrug-resistant
strains of P. falciparum, with 42 day cure rates of 100%
in one study [50]. The only concern with this combina-
tion is that it is usually not affordable for most resource
limited settings. For the second and third trimester of
pregnancy, quinine monotherapy seems to have unac-
ceptably low efficacy in areas with multidrug resistant
malaria when compared to ACT. Studies in these
regions have shown that ACT performs better than oral
quinine in terms of parasite clearance and fever clear-
ance. Two studies in Thailand [56,57] reported fewer
treatment failures at day 63 with artesunate plus atova-
quone-proguanil and artesunate plus mefloquine, when
compared with quinine. The occurrence of adverse
events experienced by the pregnant women was similar
in all groups, although tinnitus was more frequent in
the quinine group. In these studies, the considerably
inferior efficacy of quinine was attributed to both drug
resistance and to the varying pharmacokinetic properties
of quinine during pregnancy. In Africa however, avail-
able evidence suggests that Plasmodium. falciparum
generally remains sensitive to quinine [58] and low cure
rates with quinine monotherapy in pregnant women has
been mainly attributed to poor compliance to treatment
[59]. Thus in Africa, quinine monotherapy remains the
most widely used treatment for malaria in the first tri-
mester of pregnancy and is also considered safe during
all trimesters of pregnancy. A recent study from Uganda
provides important reassurance of continued efficacy of
quinine monotherapy in these regions of Africa. In this
study, quinine and artemether-lumefantrine had similar
efficacy for the treatment of uncomplicated malaria in
the second and third trimesters of pregnancy [60]. The
evidence for safety of ACT use during the first trimester
of pregnancy is currently limited [61]. Therefore, until
more data become available, the recommendation to use
quinine in the first trimester of pregnancy will remain
and ACT should only be used in the second and third
trimesters of pregnancy. Patient education and counsel-
ing will however be critical to promote compliance with
therapy.
Quinine in HIV or tuberculosis infected
populations
Interactions between HIV and malaria remain a major
public health concern in areas affected by both diseases.
Very few studies have evaluated the role of quinine in
the management of malaria in HIV infected populations.
The earliest study was done in the Congo in 1986 and it
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showed malaria cure rates of 92% in HIV infected
patients treated with oral quinine with comparable
results in HIV-negative patients [62]. In a subsequent
study in the same region, no significant differences in
treatment response were observed between children
with progressive HIV infection and HIV-uninfected con-
trols treated with oral quinine [63]. Such findings and
other available data suggest that malaria treatment pol-
icy in HIV infected populations can generally follow the
standard practices. Concerns however remain about
potential interactions between anti-malarial and anti-ret-
roviral drugs. Currently, there is little published infor-
mation on the co-administration of antiretroviral
therapy (ART) and anti-malarial drugs, yet this will
become increasingly important with the rapid scale-up
of ART in Africa. In Nigeria, concurrent administration
of nevirapine and quinine led to significant reductions
in the plasma levels of quinine and elevated plasma
levels of 3-hydroxyquinine, the major metabolite of qui-
nine [64]. This could potentially reduce the efficacy of
quinine while increasing toxicity, since 3-hydroxyquinine
has higher toxicity and lower anti-malarial activity than
quinine. Interactions with ritonavir have also been
described, with concurrent administration of these drugs
leading to marked elevations in plasma levels of quinine
and decreases in levels of 3-hydroxyquinine [65]. These
results suggest the need for downward dosage adjust-
ments of quinine with concurrent administration of rito-
navir, including ritonavir-boosted protease inhibitor
regimens.
The co-existence of tuberculosis (TB), malaria and
HIV in sub-Saharan Africa and other settings causes
additional concerns about their treatment. Interactions
between rifampicin (a major component of first-line
anti-TB treatment regimens) and quinine would be
expected as rifampicin is a potent inducer of hepatic
enzymes and quinine is metabolised mainly by the
human CYP 3A isoenzyme. In vivo studies in healthy
volunteers showed that when quinine was administered
with rifampicin its mean clearance was significantly
greater and mean elimination half-life shorter [66].
Interesting observations of the effect of combined qui-
nine and rifampicin therapy were additionally reported
in Thai patients with uncomplicated malaria [67]. In
this study, parasite clearance times were shorter in the
quinine-rifampicin group than in the group given qui-
nine monotherapy, suggesting that the anti-malarial
activity of rifampicin augmented that of quinine initially.
However, recrudescence rates were five times higher in
the quinine-rifampicin group than in the quinine-alone
group[67]. These observations were explained by
marked differences in the plasma quinine concentrations
when rifampicin was combined with quinine. These
results suggest that the quinine dosage might need to be
increased in patients receiving rifampicin as an anti-TB
drug.
Concerns also exist about potential interactions with
the concurrent use of antiretroviral drugs and artemisi-
nin-based combination therapy [68-70]. Further research
and pharmacovigilance will be critical to facilitate the
development of targeted treatment recommendations.
Presently, it is not possible to elucidate advantages asso-
ciated with the use of any particular anti-malarial drug
for HIV or TB infected populations.
Quinine in the management of severe malaria
The treatment of severe malaria requires prompt, safe,
and effective intravenous anti-malarial drugs. Over the
years, quinine has been the mainstay in the treatment of
severe malaria and still remains the first line drug in
most African countries [24]. Though quinine dosing
regimens have varied, the WHO recommends a dose of
20 mg salt/kg by intravenous infusion, then 10 mg/kg
every eight hours [23]. The rationale for the loading
dose is the urgent need to achieve therapeutic plasma
concentrations. One systematic review showed that a
loading dose of quinine reduced fever and parasite clear-
ance times, but there was insufficient data to demon-
strate its impact on risk of death [71].
More recently, intravenous artesunate is the recom-
mended treatment of choice for severe falciparum
malaria in adults [23]. This recommendation was made
on the basis of the dramatic results of the SEAQUA-
MAT trial conducted in Southeast Asia that showed a
35% reduction in the case-fatality rate in adults with
severe malaria treated with intravenous artesunate com-
pared to intravenous quinine[20]. Subsequent systematic
reviews have also provided additional evidence for this
recommendation [72]. However, about 80% of malaria
deaths occur in sub-Saharan Africa among children
aged < 5 years. The therapeutic options previously
recommended by WHO for the paediatric group
included intravenous artesunate, intramuscular arte-
mether or intravenous quinine[23]. Several trials and
meta-analyses comparing intramuscular artemether with
intravenous quinine have consistently shown no benefit
of treatment with artemether over quinine in children
with severe malaria in sub-Saharan Africa [73-75] (Table
2). The recently concluded AQUAMAT study now pro-
vides conclusive evidence of the superiority of intrave-
nous artesunate over quinine in children <15 years, with
a relative reduction of 23% in mortality associated with
the use of artesunate[21]. These observations recently
led to a change in WHO recommendations, with intra-
venous artesunate now advocated in preference to qui-
nine for the management of severe malaria in children.
The most critical issues that will need to be addressed,
however, are the availability of intravenous artesunate
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for the patients who need it, especially in resource-lim-
ited settings, and its effectiveness in real-life settings.
Until recently, the available formulations of injectable
artesunate that have been used in several clinical trials
were not produced according to Good Manufacturing
Practices (GMP) and this could be a problem for Afri-
can countries relying on donors who do not permit pur-
chase of non-GMP artesunate. WHO recently pre-
qualified intravenous artesunate manufactured by Guilin
Pharmaceuticals in China and this may resolve problems
of procurement of GMP artesunate. However, it is
unclear whether supplies will be sufficient for the thou-
sands of patients in need. Until these procurement and
supplies issues are resolved, intravenous quinine may
remain the only readily available drug for treating severe
malaria in sub-Saharan Africa and other resource-lim-
ited settings. Furthermore, there are several health sys-
tems challenges related to the management of severe
malaria in resource limited settings that impact on treat-
ment outcomes, independent of the parenteral anti-
malarial drugs used. Consequently, changes in treatment
policies, in this case from quinine to artesunate, may
not offer improvements without considering drug avail-
ability as well as additional measures to strengthen
health systems.
Another important aspect of severe malaria case man-
agement is pre-referral treatment, which is treatment
given to a patient with severe malaria before they are
referred to a health facility. This is critical, as most
malaria deaths, especially in Africa, occur outside hospi-
tals, either in the communities or at lower levels of care.
Studies evaluating the role of rectal artesunate and arte-
mether as pre-referral treatment have found these
options to be highly efficacious [76,77]. However, the
biggest challenge faced in resource limited settings has
been the non-availability of these preparations in health
facilities. A recent survey in Uganda found that rectal
artemisinins were available in only 5% of the health
facilities despite the fact that this is the recommended
pre-referral drug [78]. A feasible alternative is rectal qui-
nine, which has been found to have comparable efficacy
with intravenous quinine in the management of severe
malaria in children [79-84] (Table 2) and could play a
more significant role than currently acknowledged as
pre-referral treatment for severe malaria. More recent
studies in Senegal and Mali provide additional support
for the efficacy and feasibility of this route and also
show that a pre-referral kit of rectal quinine was accep-
table to both caretakers and health workers [85,86].
Following successful administration of parenteral
treatment for severe malaria, it is recommended to con-
tinue with an oral anti-malarial drug once a patient is
able to tolerate oral therapy. The current practice is to
continue the same medicine orally as given parenterally
to complete a full treatment course [23]. The options
for oral continuation therapy that are available in many
African settings would therefore include oral quinine or
an ACT. In non-pregnant adults, doxycyline would also
be added to either of these drugs and given twice daily
for 7 days. Where available, clindamycin may be substi-
tuted in children, since doxycyline is contraindicated in
this age group [23]. The choice of oral continuation
therapy following initial parenteral treatment of severe
malaria may also have an impact on clinical outcomes,
particularly on parasite clearance, fever clearance and
potentially the risk of recurrent parasitaemia. In this
regard completing intravenous quinine treatment with
an ACT instead of oral quinine may improve the overall
treatment outcome of parenteral quinine therapy. Stu-
dies evaluating this approach to therapy are limited. A
study in Kenya during 2000-2002, showed that complet-
ing the intravenous quinine dose with oral malarone
(atovaquone + proguanil) was associated with improved
clinical outcomes compared to intravenous quinine fol-
lowed by oral quinine [87] (Table 2). Additional studies
should explore other options, in particular ACT, for
improving therapeutic outcomes with intravenous qui-
nine treatment.
Potential explanations for quinine treatment
failure
Quinine resistance
Parasite drug resistance is probably the greatest problem
faced by malaria control programs worldwide and is an
important public health concern. Over the years, malaria
parasites have developed resistance to a number of com-
monly used anti-malarial drugs. However the develop-
ment of resistance to quinine has been slow. Although
its use started in the 17th century, resistance to quinine
was first reported in 1910 [88]. In comparison, resis-
tance to chloroquine and proguanil emerged within only
12 [89] and 1 year [88,90] of their introduction, respec-
tively. Resistance to quinine is usually low grade, with
the drug retaining some activity but having its action
delayed or diminished. Diminished sensitivity of P. falci-
parum to quinine has been widely documented in Asia
[91] and South America [92] but it seems relatively
uncommon in Africa where conflicting results of no
resistance [93,94] or varying degrees of resistance [95],
[96] have been reported. A recent study from Thailand
showed significant reductions in efficacy of quinine,
artemisinin and mefloquine when compared to previous
reports from the same area, suggesting further increase
in drug resistance in this region [97]. No convincing evi-
dence of high grade quinine resistance in the treatment
of severe malaria has been reported. Findings from a
recent systematic review of about 435 clinical trials pub-
lished between 1966 and 2002 showed that the
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recrudescence rates for quinine reported over these past
30 years remained roughly constant [98]. These findings
are encouraging and may suggest that efficacy of quinine
has been preserved.
Variations in quinine pharmacokinetics
Treatment failures with quinine could also be explained
by varying pharmacokinetic profiles of the drug. It is
known that quinine pharmacokinetic properties and
therapeutic responses vary with age, pregnancy, immu-
nity and disease severity [99]. Also, as patients recover
from malaria, there is usually an expansion of the
volume of distribution and an increase in systemic clear-
ance of quinine resulting in a decline in the average
concentration of quinine in plasma [100]. These varia-
tions may lead to drug levels that may be inadequate to
completely clear infection. The possibility that pharma-
cokinetic factors may explain quinine treatment failure
was initially raised about 20 years ago when a Thai
patient who had fatal severe malaria and apparent RIII
resistance was found to have abnormally low levels of
quinine despite adequate dosing [101]. Additional evi-
dence for the impact of unusual quinine pharmacoki-
netics on treatment outcomes was provided by a more
Table 2 Summary of studies of quinine for the treatment of severe malaria
Study site Year Sample size and
Study
population
Drug
Regimens
Treatment outcome Comment Reference
Gambia 1992-
1994
576 children
1-9 years Cerebral
malaria
Intramuscular
artemether
(IMA)
Intravenous
quinine (IVQ)
Mortality:
IMA:20.5%
IVQ: 21.5%
Neurological sequelae:
IMA: 3.3%
IVQ: 5.3%
Artemether is as effective as quinine in treatment
of cerebral malaria in children
[74]
Malawi 1992-
1994
183 children
Cerebral malaria
Intramuscular
artemether
(IMA)
Intravenous
quinine (IVQ)
Mortality:
IMA: 11%
IVQ: 16%
Survival with
neurological sequelae:
IMA: 19%
IVQ: 12%
Results do not suggest artemether would confer a
survival advantage over quinine
[73]
Kenya 2000-
2002
360 patients
1-60 years
Severe malaria
IV Quinine +
oral malarone
(QM)
IV Quinine +oral
quinine (QQ)
Day 28 cure rates:
QM: 98.7%
QQ: 90%
Using malarone after IV quinine is safer and as
effective as IV quinine +oral quinine
[87]
Burkina
Faso
2001-
2002
898 children
1-15 years
Moderately severe
malaria
Rectal quinine
(RQ)
Intramuscular
quinine (IMQ)
Early treatment failure
(day 3):
RQ: 6%
IMQ: 3%
Fever recurrence on day
7:
RQ: 5%
IMQ: 10%
Rectal quinine had acceptable safety profile and
could be used as early treatment for severe
malaria
[84]
Uganda 2002-
2003
103 children
0.5-5 years
Cerebral malaria
Rectal
artemether (RA)
Intravenous
quinine (IVQ)
Mortality:
IVQ: 11.7%
RA: 19.2%
Rectal artemether was effective and well tolerated [76]
S.E Asia
(Four
countries)
2003-
2005
1461 patients
>2 years
Severe malaria
Intravenous
artesunate (IVA)
Intravenous
quinine (IVQ)
Mortality:
IVA: 15%
IVQ: 22%
Absolute reduction in
mortality: 34.7%
Intravenous artesunate should be treatment of
choice for severe malaria in adults
[20]
Uganda 2003-
2004
110 children
0.5-5 years
Cerebral malaria
Rectal quinine
(RQ)
Intravenous
quinine (IVQ)
Mortality:
RQ: 7%
IVQ: 9%
Comparable clinical and
parasitological outcomes
Rectal quinine was efficacious and could be used
as a treatment alternative
[79]
Africa (Nine
countries)
2005-
2010
5425 children
< 15 years Severe
malaria
Intravenous
artesunate (IVA)
Intravenous
quinine (IVQ)
Mortality:
IVA: 8.5%
IVQ: 10.9%
Relative reduction in
mortality: 22.5%
Parenteral artesunate should replace quinine as
the treatment of choice for severe malaria
[21]
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recent study describing early treatment failure in a
patient with severe malaria with an abnormally high
volume of distribution and increased quinine clearance,
resulting in abnormally low quinine concentrations
[102]. A few studies have proposed that an increase in
the quinine dosage after the third day could compensate
for declines in plasma drug levels during recovery, espe-
cially in areas with resistant P. falciparum [99]. How-
ever, this is not routinely practiced. Despite these
anecdotal observations, there is little evidence for large
variations in quinine pharmacokinetics [103] and the
exact role that variations in drug levels play in quinine
treatment responses is unclear.
Quinine drug quality and treatment compliance
The quality of quinine used in routine care could play a
key role in clinical outcomes. Poor quality drugs remain
a problem worldwide and are a serious public health
threat. A study in Nigeria evaluating the quality of dif-
ferent anti-malarial drugs found that 37% of 225 anti-
malarial drugs did not meet the tolerance limits set by
United Sates Pharmacopeia (USP) for the amount of
active ingredient, and 46% of these were formulations of
quinine [104]. In Congo, Burundi and Angola only 89%
of the declared active substance was found in quinine
tablets, with high quantities of impurities reported [105].
Another worrying situation was unveiled in a survey in
Cameroon, where nearly 74% of 70 quinine samples had
no active ingredient [106]. Several other studies have
also described varying problems with quinine drug qual-
ity in different settings [107,108]. Ideally, branded anti-
malarial drugs should be used, but unfortunately,
branded quinine products are not universally available
in Africa and other malaria endemic settings. In addi-
tion, national drug regulators need to strengthen their
roles in the monitoring of anti-malarial drug quality.
Another potential explanation for quinine treatment
failures may be poor compliance. Quinine’s prolonged
treatment course and significant tolerability problems
may lead to poor compliance, and hence poor therapeutic
outcomes [32,45,59]. In this aspect, ACT has an advan-
tage over quinine since it is administered once or twice
daily over three days. A recent study in Uganda showed
comparable compliance on day 3 of treatment in patients
taking either quinine or artemether-lumefantrine. How-
ever, non-compliance to quinine greatly increased with
increasing days on therapy to about 44% by day 7[45].
Promotion of shorter courses of quinine, especially in
combination with antibiotics, should improve compliance
as well as treatment outcomes [39,109].
Conclusion
In the near future, quinine will continue to play a signif-
icant role in the management of malaria, particularly in
resource limited settings. Following the results of the
SEAQUAMAT and AQUAMAT trials, artesunate is
now recommended as the treatment of choice for severe
malaria patients, with quinine only acting as an alterna-
tive when artesunate is not available. The role of rectal
quinine as pre-referral treatment for severe malaria has
not been fully explored, but this remains a promising
intervention given the limited availability of rectal arte-
misinin preparations in resource limited settings. Qui-
nine continues to play a critical role in the management
of malaria in the first trimester of pregnancy, and will
remain so until safer alternatives become available. The
continued use of quinine in the management of uncom-
plicated malaria is a concern. Clearly, the seven day
duration of therapy and thrice daily administration of
quinine present a major challenge to completion of
therapy, leading to sub-optimal treatment outcomes. In
these situations, ACT is a better option given the sim-
plicity of dosing and shorter treatment duration. How-
ever, because of the frequent ACT stock outs, the rapid
withdrawal of quinine as a treatment option for uncom-
plicated malaria cases is risky. The best approach would
be, besides improving the supply system, to maintain
quinine as a fall-back drug in case of ACT stock-outs.
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